Pregnancy in Polycystic Ovary Syndrome II

Condition(s) targeted: Pregnancy; Polycystic Ovary Syndrome

Intervention: Clomiphene citrate (Drug); Letrozole (Drug)

Phase: Phase 3

Status: Recruiting

Sponsored by: Yale University

Official(s) and/or principal investigator(s):
Esther Eisenberg, MD, MPH, Study Director, Affiliation: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Nanette Santoro, MD, Study Chair, Affiliation: Albert Einstein College of Medicine of Yeshiva University
Richard Legro, MD, Principal Investigator, Affiliation: Pennsylvania State University College of Medicine
Robert Brzyski, MD, PhD, Study Director, Affiliation: University of Texas
Peter Casson, MD, Study Director, Affiliation: University of Vermont
Michael Diamond, MD, Study Director, Affiliation: Wayne State University
Heping Zhang, PhD, Study Director, Affiliation: Yale University
Gregory M Christman, MD, Study Director, Affiliation: University of Michigan
Christos Coutifaris, MD, Study Director, Affiliation: University of Pennsylvania
William D Schlaff, MD, Study Director, Affiliation: University of Colorado Denver Health Science Center

Overall contact:
Heping Zhang, PHD, Phone: (203) 785-5185, Email: rmn-Coordinators@panlists.yale.edu

The primary research hypothesis is that ovulation induction with an aromatase inhibitor (letrozole) is more likely to result in live birth than ovulation induction with a selective estrogen receptor modulator (clomiphene citrate) in infertile women with PCOS. A safety hypothesis will also be incorporated into the primary research hypothesis in which we hypothesize both treatments are equally safe for mother and child.

Secondary research hypotheses include:

1. Treatment with letrozole is more likely to result in singleton pregnancy compared to treatment with clomiphene citrate. Singleton pregnancy is defined as presence of a single intrauterine gestational sac with a single fetal pole and observable heart motion.

2. Treatment with letrozole will less likely result in a first trimester intrauterine fetal demise than treatment with clomiphene citrate. A first trimester IUFD is defined as a pregnancy that ends before 13 weeks gestation.

3. Treatment with letrozole is more likely to result in ovulation (increased ovulation rate) compared to treatment with clomiphene citrate. Ovulation is defined as a midluteal progesterone level ≥ 3 ng/mL.

4. The shortest time to pregnancy will be with letrozole.

5. Age, body mass index, SHBG, testosterone, LH, Anti-Mullerian Hormone (AMH), and degree of hirsutism and acne will be significant predictors of ovulation and conception regardless of treatment.

6. Improvement in SHBG, testosterone, AMH, and LH levels will be significant predictors of ovulation and conception regardless of treatment.

7. DNA polymorphisms in estrogen action genes will predict response to study drug.

8. Quality of Life will be better on letrozole than clomiphene.

9. Letrozole will be more cost effective at achieving singleton pregnancies than clomiphene.

Official title: A 20 Week Double-Blind Randomized Trial of Clomiphene Citrate and Letrozole for the Treatment of Infertility in Women With Polycystic Ovary Syndrome

Study design: Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment, Efficacy Study

Primary outcome: The primary outcome measure is the occurrence of a live birth during the study period. Safety measures will be the number and type of reported adverse events in subjects and offspring.

Secondary outcome:

Singleton live birth rate

Abortion rate

Time to pregnancy

Ovulation rate

Pregnancy complication rate

Birth weight

Neonatal complication rate

DNA polymorphisms

Quality of life

Cost effectiveness

Detailed description: Preliminary data are promising for the use of letrozole to induce ovulation in infertile women with PCOS. However the true magnitude of the effect of letrozole is difficult to discern from prior studies. Therefore we intend to determine the safety and efficacy of letrozole, an aromatase inhibitor, compared to clomiphene citrate, a selective estrogen receptor modulator, in achieving live birth in infertile women with PCOS.

Treatment- After progestin withdrawal, 750 women will be equally randomized to two different treatment arms: A) clomiphene citrate 50 mg every day for 5 days (day 3-7 of cycle), or B) letrozole 2. 5 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks. Dose will be increased in subsequent cycles in both treatment groups for non-response or poor ovulatory response up to a maximum of 150 mg of clomiphene a day (x 5 days) or 7. 5 mg of letrozole a day (x 5 days).

Statistical Analysis- The primary analysis will use an intent-to-treat approach to examine differences in the live birth rate in the two treatment arms.

Anticipated time to completion- A total of 4 years will be required to complete the study after start up; 31 month enrollment period, 5 month treatment period, with 9 month additional observation to determine pregnancy outcomes. This will be accomplished by enrolling ~3. 45 women with PCOS per center per month over the enrollment period (N = 7 RMN sites).

Minimum age: 18 Years. Maximum age: 40 Years. Gender(s): Female.

Criteria:

The patient population will consist of 750 infertile women with PCOS with ovulatory dysfunction and either one of the remaining two criteria, hyperandrogenism (clinical or biochemical) or polycystic ovaries on ultrasound, with exclusion of secondary causes of PCOS. Additionally, the couple will have no other major infertility factor, and the subject will have at least one patent fallopian tube and a normal uterine cavity, and a partner with a sperm concentration of 14 million/mL in at least one ejaculate.

Inclusion Criteria:

- Key Inclusion Criteria (Must have ovulatory dysfunction and either hyperandrogenism

or PCO)

1. Chronic anovulation or oligomenorrhea: defined as spontaneous intermenstrual periods of ≥45 days or a total of ≤8 menses per year, or for women with suspected anovulatory bleeding, a midluteal serum progesterone level < 3 ng/dL is indicative of chronic anovulation. For women who have been on ovarian suppressive therapy or other confounding medication (i. e. insulin sensitizing agents) within the last year prior to the study, a history of ≤8 menses per year prior to the initiation of this prior therapy will qualify as evidence of oligomenorrhea. For women with more regular bleeding patterns, but who are suspected to be experiencing anovulatory bleeding, a midluteal progesterone level < 3ng/dL will be evidence of ovulatory dysfunction and qualify as anovulation.

2. Hyperandrogenism (either Hirsutism or Hyperandrogenemia) or Polycystic Ovaries on Ultrasound:

1. Hirsutism is determined by a modified Ferriman-Gallwey Score >8 at screening exam (Hatch, Rosenfield et al. 1981 Aug 1). Subjects who have hirsutism do not need local or core labs documenting elevated androgen levels.

2. Hyperandrogenemia will be defined as an elevated total testosterone, or free androgen index (FAI). Outside lab values obtained within the last year documenting elevated T or FAI levels are sufficient to meet criteria of hyperandrogenemia.

3. Polycystic Ovaries on Ultrasound: PCO will be defined as either an ovary that contains 12 or more follicles measuring 2-9 mm in diameter, or an increased ovarian volume (> 10 cm3) on one ovary for entry into the study. If there is a follicle > 10 mm in diameter, the scan should be repeated at a time of ovarian quiescence in order to calculate volume and area if the subject does not otherwise qualify for the study. The presence of a single polycystic ovary (PCO), either by volume or morphology, is sufficient to provide the diagnosis.

Exclusion Criteria:

- We will exclude subjects with medical conditions that represent contraindications to

CC, aromatase inhibitors and/or pregnancy or who are unable to comply with the study procedures. We will exclude subjects with poorly controlled Type 1 or 2 diabetes; undiagnosed liver disease or dysfunction (based on serum liver enzyme testing); renal disease or abnormal serum renal function; significant anemia; history of deep venous thrombosis, pulmonary embolus, or cerebrovascular accident; uncontrolled hypertension, known symptomatic heart disease; history of or suspected cervical carcinoma, endometrial carcinoma, or breast carcinoma; undiagnosed vaginal bleeding, and use of other medications known to affect reproductive function or metabolism (e. g., OCP, GnRH agonists and antagonists, anti-androgens, gonadotropins, anti-obesity drugs, somatostatin, diazoxide, ACE inhibitors, and calcium channel blockers). As in PPCOS we will allow a 3 mos washout period for subjects who desire to participate and discontinue exclusionary medications (most commonly OCP, but also possibly metformin), and a period of observation or treatment for correctable conditions.

Heping Zhang, PHD, Phone: (203) 785-5185, Email: rmn-Coordinators@panlists.yale.edu

University of Colorado, Aurora,, Colorado 80045, United States; Recruiting
William Schlaff, MD, Phone: 303-724-2037, Email: william.schlaff@ucdenver.edu
Cyndi Long, MS, RD, CCRC, Phone: (303) 724-2064, Email: cyndi.long@ucdenver.edu
William Schlaff, MD, Principal Investigator
Randall Meacham, MD, Sub-Investigator

Yale University, New Haven, Connecticut 06511, United States; Not yet recruiting
Heping Zhang, PhD, Phone: 203-785-5185, Email: heping.zhang@yale.edu
Meizhuo Zhang, PhD, Phone: (203) 785-6759, Email: meizhuo.zhang@yale.edu
Heping Zhang, PhD, Principal Investigator
Robert Makuch, PhD, Sub-Investigator
Pasquale Patrizio, MD, MBE, Sub-Investigator
Lawrency Scahill, PhD, Sub-Investigator
Hugh Taylor, MD, Sub-Investigator

University of Michigan, Ann Arbor, Michigan 48109, United States; Recruiting
Bev Marchant, Phone: 734-998-4973, Email: bevm@umich.edu
Gregory Christman, MD, Email: growthh@umich.edu
Gregory Christman, MD, Principal Investigator
Dana Ohl, MD, Sub-Investigator
Senait Fisseha, MD, Sub-Investigator
John Randolph, MD, Sub-Investigator
Yolanda Smith, MD, Sub-Investigator
Anjel Vahratian, PhD, MPH, Sub-Investigator

Wayne State University, Detroit, Michigan 48201, United States; Recruiting
Michael Diamond, MD, Phone: 313-993-4523, Email: mdiamond@med.wayne.edu
Karen Collins, MS, Phone: (313) 993-8706, Email: kcollins@med.wayne.edu
Michael Diamond, MD, Principal Investigator
Joel Ager, PhD, Sub-Investigator
Stephen Krawetz, PhD, Sub-Investigator
Laura Detti, MD, Sub-Investigator
Elizabeth Puscheck, MD, Sub-Investigator
Frank Yelian, MD, PhD, Sub-Investigator
Terri Woodard, MD, Sub-Investigator

Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033, United States; Recruiting
Richard Legro, MD, Phone: 717-531-8478, Email: RSL1@PSU.EDU
Jamie Ober, RN, Phone: (717) 531-6272, Email: JOBER@hmc.psu.edu
Richard Legro, MD, Principal Investigator
J.C. Trussel, MD, Sub-Investigator

University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States; Recruiting
Christos Coutifaris, MD, PhD, Phone: 215-662-2977, Email: ccoutifaris@obgyn.upenn.edu
Linda Martino, MSN, CRNP, Phone: (215) 615-3364, Email: lmartino@obgyn.upenn.edu
Christos Coutifaris, MD, PhD, Principal Investigator
Kurt Barnhart, MD, MSCE, Sub-Investigator
Peter Snyder, MD, Sub-Investigator
Mary Sammel, PhD, Sub-Investigator
William Stauffer, Sub-Investigator

University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229, United States; Recruiting
Robert Brzyski, MD, PhD, Phone: 210-567-6121, Email: brzyski@uthscsa.edu
Carann Easton, RN, Phone: (210) 567-6245, Email: eastonc@uthscsa.edu
Robert Brzyski, MD, PhD, Principal Investigator
John Case, MD, Sub-Investigator
Brad Pollock, PhD, MPH, Sub-Investigator

University of Vermont, Burlington, Vermont 05405, United States; Recruiting
Peter Casson, MD, Phone: 802-847-3450, Email: peter.casson@vtmednet.org
Jennifer Crossmon, Phone: (802) 656-2272, Email: jennifer.crossmon@uvm.edu
Peter Casson, MD, Principal Investigator
Thomas Jackson, MD, Sub-Investigator
Taka Ashikaga, PhD, Sub-Investigator
Michael Toth, PhD, Sub-Investigator

Starting date: February 2009
Ending date: February 2013
Last updated: October 14, 2009